Mira Pharmaceuticals (MIRA) Share-based Compensation (2022 - 2025)
Mira Pharmaceuticals (MIRA) posted Share-based Compensation of $4.3 million for Q4 2025, up 3340.77% sequentially from $124972.0 in Q3 2025, and up 686.42% YoY from $546781.0 in Q4 2024.
Mira Pharmaceuticals (MIRA) Share-based Compensation (2022 - 2025) Analysis & Trends
Mira Pharmaceuticals (MIRA) has 4 years of Share-based Compensation data on file, last reported at $4.3 million in Q4 2025.
- Quarterly Share-based Compensation rose 686.42% year-over-year to $4.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.8 million (up 203.26% YoY) and the FY2025 annual result came in at $6.1 million, up 217.58% from the prior year.
- Share-based Compensation grew to $4.3 million in Q4 2025 per MIRA's latest filing, from $124972.0 in the prior quarter.
- The five-year high for Share-based Compensation was $4.3 million in Q4 2025, with the low at $124972.0 in Q3 2025.
- Average Share-based Compensation over 4 years is $756594.5, with a median of $512699.0 recorded in 2024.
- Year-over-year, Share-based Compensation jumped 882.5% in 2023 and tumbled 81.47% in 2024.
- Mira Pharmaceuticals' Share-based Compensation stood at $147800.0 in 2022, then surged by 44.66% to $213813.0 in 2023, then surged by 155.73% to $546781.0 in 2024, then surged by 686.42% to $4.3 million in 2025.
- Business Quant data shows MIRA's Share-based Compensation at $4.3 million in Q4 2025, $124972.0 in Q3 2025, and $525188.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 161.00 Mn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 300.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 444.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 185.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 218.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 272.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Mira Pharmaceuticals | 22.51 Mn | 11.48 Mn | - | 4.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.30 Mn |
| Dec 31, 2025 | 4.30 Mn |
| Sep 30, 2025 | 124,972.00 |
| Sep 30, 2025 | 124,972.00 |
| Jun 30, 2025 | 525,188.00 |
| Jun 30, 2025 | 525,188.00 |
| Mar 31, 2025 | 874,812.00 |
| Mar 31, 2025 | 874,812.00 |
| Dec 31, 2024 | 546,781.00 |
| Dec 31, 2024 | 546,781.00 |
| Sep 30, 2024 | 269,011.00 |
| Sep 30, 2024 | 269,011.00 |
| Jun 30, 2024 | 604,803.00 |
| Jun 30, 2024 | 604,803.00 |
| Mar 31, 2024 | 500,210.00 |
| Mar 31, 2024 | 500,210.00 |
| Dec 31, 2023 | 213,813.00 |
| Dec 31, 2023 | 213,813.00 |
| Sep 30, 2023 | 1.45 Mn |
| Sep 30, 2023 | 1.45 Mn |